700 related articles for article (PubMed ID: 16913090)
41. The influence of previous orbital irradiation on the outcome of rehabilitative decompression surgery in graves orbitopathy.
Baldeschi L; MacAndie K; Koetsier E; Blank LE; Wiersinga WM
Am J Ophthalmol; 2008 Mar; 145(3):534-540. PubMed ID: 18191092
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
43. Endocrine ophthalmopathy and radioiodine therapy.
Karlsson FA
Acta Oncol; 2006; 45(8):1046-50. PubMed ID: 17118837
[TBL] [Abstract][Full Text] [Related]
44. [Graves' ophthalmopathy].
Eckstein A; Dekowski D; Führer-Sakel D; Berchner-Pfannschmidt U; Esser J
Ophthalmologe; 2016 Apr; 113(4):349-64; quiz 465-6. PubMed ID: 27059986
[TBL] [Abstract][Full Text] [Related]
45. Evaluating Graves' orbitopathy.
Dolman PJ
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):229-48. PubMed ID: 22632361
[TBL] [Abstract][Full Text] [Related]
46. Diagnosis of exophthalmos using orbital ultrasonography and treatment of malignant exophthalmos with steroid therapy, orbital radiation therapy, and plasmapheresis.
Yamamoto K; Saito K; Takai T; Yoshida S
Prog Clin Biol Res; 1983; 116():189-205. PubMed ID: 6134291
[TBL] [Abstract][Full Text] [Related]
47. Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.
Lanzolla G; Menconi F; Nicolì F; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Dec; 44(12):2575-2579. PubMed ID: 33844165
[TBL] [Abstract][Full Text] [Related]
48. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
49. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
50. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?
Bartalena L
Clin Endocrinol (Oxf); 2010 Aug; 73(2):149-52. PubMed ID: 20148907
[TBL] [Abstract][Full Text] [Related]
51. Advances in the pharmacological treatment of Graves' orbitopathy.
Ruchała M; Sawicka-Gutaj N
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):981-9. PubMed ID: 26966785
[TBL] [Abstract][Full Text] [Related]
52. [Intravenous immunoglobulins treatment of patients with Graves' ophthalmopathy].
Leibe A; Levy Y; Shoenfeld Y
Harefuah; 2001 May; 140(5):392-4, 455, 454. PubMed ID: 11419058
[TBL] [Abstract][Full Text] [Related]
53. Orbital lymphoma associated with Graves' disease: A case report.
Hajduković Z; Kuzmić-Janković S; Kljaković-Avramović T; Sekulović L; Tukić L
Vojnosanit Pregl; 2014 May; 71(5):510-4. PubMed ID: 26137719
[TBL] [Abstract][Full Text] [Related]
54. Exophthalmos in a young woman with no graves' disease - a case report of IgG4-related orbitopathy.
Erdei A; Steiber Z; Molnar C; Berenyi E; Nagy EV
BMC Ophthalmol; 2018 Jan; 18(1):5. PubMed ID: 29329570
[TBL] [Abstract][Full Text] [Related]
55. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
56. Management plan and delivery of care in Graves' ophthalmopathy patients.
Yang M; Perros P
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):303-11. PubMed ID: 22632367
[TBL] [Abstract][Full Text] [Related]
57. Editorial. Graves' orbitopathy.
von Arx GF
Orbit; 2009; 28(4):209-13. PubMed ID: 19839876
[No Abstract] [Full Text] [Related]
58. Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis.
Oeverhaus M; Winkler L; Stähr K; Daser A; Bechrakis N; Stöhr M; Chen Y; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1160172. PubMed ID: 37082130
[TBL] [Abstract][Full Text] [Related]
59. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
60. [Endocrine orbitopathy].
Fierz A; Landau K
Praxis (Bern 1994); 2001 May; 90(20):882-6. PubMed ID: 11416973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
